文献速递泌尿男性生殖肿瘤

短期与中期雄激素抑制联合放疗、联合或不联合唑来膦酸治疗局部晚期前列腺癌(TROG 03.04 RADAR):随机3期析因试验的10年结果

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
PubMed 文献 · Lancet Oncol · 2018-12-19

RADAR试验纳入1071例局部晚期前列腺癌患者,随机分配至6个月或18个月雄激素抑制联合放疗,联合或不联合唑来膦酸。10年随访显示,18个月雄激素抑制较6个月降低前列腺癌特异性死亡率(绝对差异3.7%),唑来膦酸无获益。

要点

  • 18个月雄激素抑制较6个月降低前列腺癌特异性死亡累积发生率(9.7% vs 13.3%)。
  • 唑来膦酸未影响前列腺癌特异性死亡率(11.2% vs 11.7%)。
  • 唑来膦酸组发生1例下颌骨坏死,严重不良事件总数达3例。

核心结论

  • 18个月雄激素抑制联合放疗较6个月雄激素抑制联合放疗是更有效的治疗选择,但加用唑来膦酸无获益。

研究设计与样本

  • 随机、3期、2×2析因试验,纳入1071例局部晚期前列腺癌男性,随机分配至四个治疗组。

主要发现

  • 中位随访10.4年(IQR 7.9-11.7),共死亡375例(6AS+RT组200例,18AS+RT组175例),其中143例(38%)归因于前列腺癌(6AS+RT组81例,18AS+RT组62例)。
  • 前列腺癌特异性死亡调整累积发生率:6AS+RT组13.3%(95% CI 10.3-16.0)vs 18AS+RT组9.7%(95% CI 7.3-12.0),绝对差异3.7%(95% CI 0.3-7.1;sHR 0.70 [95% CI 0.50-0.98],调整p=0.035)。
  • 唑来膦酸组前列腺癌特异性死亡调整累积发生率11.2%(95% CI 8.7-13.7)vs 无唑来膦酸组11.7%(95% CI 9.2-14.1),绝对差异-0.5%(95% CI -3.8至2.9;sHR 0.95 [95% CI 0.69-1.32],调整p=0.78)。
  • 自上次报告以来新发1例严重不良事件(下颌骨坏死,发生于接受18个月雄激素抑制联合唑来膦酸的患者),该严重不良事件总例数达3例(接受唑来膦酸安全性评估的530例患者中<1%),药物相关严重不良事件总例数为12例(所有1065例可评估安全性患者中1%)。
  • 研究期间无治疗相关死亡。

关键数值与推荐

  • 18个月雄激素抑制联合放疗较6个月雄激素抑制联合放疗降低前列腺癌特异性死亡风险(sHR 0.70,95% CI 0.50-0.98)。
  • 唑来膦酸对前列腺癌特异性死亡率无显著影响(sHR 0.95,95% CI 0.69-1.32)。

临床怎么用

  • 作者认为,18个月雄激素抑制联合放疗是局部晚期前列腺癌更有效的治疗选择,但加用唑来膦酸无获益。
  • 作者指出,RADAR与French Canadian Prostate Cancer Study IV试验证据提示,18个月雄激素抑制联合中度放疗剂量递增是有效且较长时间雄激素抑制更可耐受的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal duration of androgen suppression for men with locally advanced prostate cancer receiving radiotherapy with curative intent is yet to be defined. Zoledronic acid is effective in preventing androgen suppression-induced bone loss, but its role in preventing castration-sensitive bone metastases in locally advanced prostate cancer is unclear. The RADAR trial assessed whether the addition of 12 months of adjuvant androgen suppression, 18 months of zoledronic acid, or both, can improve outcomes in men with locally advanced prostate cancer who receive 6 months of androgen suppression and prostatic radiotherapy. This report presents 10-year outcomes from this trial. METHODS: For this randomised, phase 3, 2 × 2 factorial trial, eligible men were 18 years or older with locally advanced prostate cancer (either T2b-4, N0 M0 tumours or T2a, N0 M0 tumours provided Gleason score was ≥7 and baseline prostate-specific antigen [PSA] concentration was ≥10 μg/L). We randomly allocated participants in a 2 × 2 factorial design by computer-generated randomisation (using the minimisation technique, and stratified by centre, baseline PSA concentration, clinical tumour stage, Gleason score, and use of a brachytherapy boost) in a 1:1:1:1 ratio to four treatment groups. Patients in the control group received 6 months of neoadjuvant androgen suppression with leuprorelin (22·5 mg every 3 months, intramuscularly) and radiotherapy alone (short-term androgen suppression [STAS]); this treatment was either followed by another 12 months of adjuvant androgen suppression with leuprorelin (22·5 mg every 3 months, intramuscularly; intermediate-term androgen suppression [ITAS]), or accompanied by 18 months of zoledronic acid (4 mg every 3 months, intravenously) starting at randomisation (STAS plus zoledronic acid), or both (ITAS plus zoledronic acid). All patients received radiotherapy to the prostate and seminal vesicles, starting from the end of the fifth month of androgen suppression; dosing options were 66, 70, and 74 Gy in 2-Gy fractions per day, or 46 Gy in 2-Gy fractions followed by a high-dose-rate brachytherapy boost dose of 19·5 Gy in 6·5-Gy fractions. Treatment allocation was open label. The primary endpoint was prostate cancer-specific mortality and was analysed according to intention-to-treat using competing-risks methods. The trial is closed to follow-up and this is the final report of the main endpoints. This trial is registered with ClinicalTrials.gov, number NCT00193856. FINDINGS: Between Oct 20, 2003, and Aug 15, 2007, 1071 men were enrolled and randomly assigned to STAS (n=268), ITAS (n=268), STAS plus zoledronic acid (n=268), and ITAS plus zoledronic acid (n=267). Median follow-up was 10·4 years (IQR 7·9-11·7). At this 10-year follow-up, no interactions were observed between androgen suppression and zoledronic acid so the treatment groups were collapsed to compare treatments according to duration of androgen suppression: 6 months of androgen suppression plus radiotherapy (6AS+RT) versus 18 months of androgen suppression plus radiotherapy (18AS+RT) and to compare treatments according to whether or not patients received zoledronic acid. The total number of deaths was 375 (200 men receiving 6AS+RT and 175 men receiving 18AS+RT), of which 143 (38%) were attributable to prostate cancer (81 men receiving 6AS+RT and 62 men receiving 18AS+RT). When analysed by duration of androgen suppression, the adjusted cumulative incidence of prostate cancer-specific mortality was 13·3% (95% CI 10·3-16·0) for 6AS+RT versus 9·7% (7·3-12·0) for 18AS+RT, representing an absolute difference of 3·7% (95% CI 0·3-7·1; sub-hazard ratio [sHR] 0·70 [95% CI 0·50-0·98], adjusted p=0·035). The addition of zoledronic acid did not affect prostate cancer-specific mortality; the adjusted cumulative incidence of prostate cancer-specific mortality was 11·2% (95% CI 8·7-13·7) with zoledronic acid vs 11·7% (9·2-14·1) without, representing an absolute difference of -0·5% (95% CI -3·8 to 2·9; sHR 0·95 [95% CI 0·69-1·32], adjusted p=0·78). Although safety analysis was not prespecified for this 10-year analysis, one new serious adverse event (osteonecrosis of the mandible, in a patient who received 18 months of androgen suppression plus zoledronic acid) occurred since our previous report, bringing the total number of cases of this serious adverse event to three (<1% out of 530 patients who received zoledronic acid evaluated for safety) and the total number of drug-related serious adverse events to 12 (1% out of all 1065 patients evaluable for safety). No treatment-related deaths occurred during the study. INTERPRETATION: 18 months of androgen suppression plus radiotherapy is a more effective treatment option for locally advanced prostate cancer than 6 months of androgen suppression plus radiotherapy, but the addition of zoledronic acid to this treatment regimen is not beneficial. Evidence from the RADAR and French Canadian Prostate Cancer Study IV trials suggests that 18 months of androgen suppression with moderate radiation dose escalation is an effective but more tolerable option than longer durations of androgen suppression for men with locally advanced prostate cancer including intermediate and high risk elements. FUNDING: National Health and Medical Research Council of Australia, Novartis Pharmaceuticals Australia, AbbVie Pharmaceuticals Australia, New Zealand Health Research Council, New Zealand Cancer Society, Cancer Standards Institute New Zealand, University of Newcastle (Australia), Hunter Medical Research Institute, Calvary Mater Newcastle Radiation Oncology Fund, and Maitland Cancer Appeal.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Denham JW, Joseph D, Lamb DS, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2018. PMID: 30579763. doi:10.1016/S1470-2045(18)30757-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。